Search Results - "GUYADER, Charlotte"

Molecular profiling of patient-derived breast cancer xenografts by Reyal, Fabien, Guyader, Charlotte, Decraene, Charles, Lucchesi, Carlo, Auger, Nathalie, Assayag, Franck, De Plater, Ludmilla, Gentien, David, Poupon, Marie-France, Cottu, Paul, De Cremoux, Patricia, Gestraud, Pierre, Vincent-Salomon, Anne, Fontaine, Jean-Jacques, Roman-Roman, Sergio, Delattre, Olivier, Decaudin, Didier, Marangoni, Elisabetta

“…Identification of new therapeutic agents for breast cancer (BC) requires preclinical models that reproduce the molecular characteristics of their respective…”
Get full text

BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance by Jaspers, Janneke E, Sol, Wendy, Kersbergen, Ariena, Schlicker, Andreas, Guyader, Charlotte, Xu, Guotai, Wessels, Lodewyk, Borst, Piet, Jonkers, Jos, Rottenberg, Sven

“…Pan- or multidrug resistance is a central problem in clinical oncology. Here, we use a genetically engineered mouse model of BRCA2-associated hereditary breast…”
Get full text

A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays by MARANGONI, Elisabetta, VINCENT -SALOMON, Anne, REBUCCI, Magali, TRAN -PERENNOU, Carine, SASTRE-GARAU, Xavier, SIGAL-ZAFRANI, Brigitte, DELATTRE, Olivier, DIBRAS, Véronique, POUPON, Marie-France, AUGER, Nathalie, DEGEORGES, Armelle, ASSAYAG, Franck, DE CREMOUX, Patricia, DE PLATER, Ludmilla, GUYADER, Charlotte, DE PINIEUX, Gonzague, JUDDE, Jean-Gabriel

“…Purpose: To establish a panel of human breast cancer (HBC) xenografts in immunodeficient mice suitable for pharmacologic preclinical assays. Experimental…”
Get full text

Selected Alkylating Agents Can Overcome Drug Tolerance of G0-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice by Pajic, Marina, Blatter, Sohvi, Guyader, Charlotte, Gonggrijp, Maaike, Kersbergen, Ariena, Küçükosmanoğlu, Aslι, Sol, Wendy, Drost, Rinske, Jonkers, Jos, Borst, Piet, Rottenberg, Sven

“…Abstract Purpose: We aimed to characterize and target drug-tolerant BRCA1-deficient tumor cells that cause residual disease and subsequent tumor relapse…”
Get full text

Haploid genetic screens identify genetic vulnerabilities to microtubule‐targeting agents by Gerhards, Nora M., Blomen, Vincent A., Mutlu, Merve, Nieuwenhuis, Joppe, Howald, Denise, Guyader, Charlotte, Jonkers, Jos, Brummelkamp, Thijn R., Rottenberg, Sven

“…The absence of biomarkers to accurately predict anticancer therapy response remains a major obstacle in clinical oncology. We applied a genome‐wide…”
Get full text

Risk of hormone escape in a human prostate cancer model depends on therapy modalities and can be reduced by tyrosine kinase inhibitors by Guyader, Charlotte, Céraline, Jocelyn, Gravier, Eléonore, Morin, Aurélie, Michel, Sandrine, Erdmann, Eva, de Pinieux, Gonzague, Cabon, Florence, Bergerat, Jean-Pierre, Poupon, Marie-France, Oudard, Stéphane

“…Almost all prostate cancers respond to androgen deprivation treatment but many recur. We postulated that risk of hormone escape--frequency and delay--are…”
Get full text

Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs by Planells-Cases, Rosa, Lutter, Darius, Guyader, Charlotte, Gerhards, Nora M, Ullrich, Florian, Elger, Deborah A, Kucukosmanoglu, Asli, Xu, Guotai, Voss, Felizia K, Reincke, S Momsen, Stauber, Tobias, Blomen, Vincent A, Vis, Daniel J, Wessels, Lodewyk F, Brummelkamp, Thijn R, Borst, Piet, Rottenberg, Sven, Jentsch, Thomas J

“…Although platinum‐based drugs are widely used chemotherapeutics for cancer treatment, the determinants of tumor cell responsiveness remain poorly understood…”
Get full text

Selected Alkylating Agents Can Overcome Drug Tolerance of G 0 -like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice by Pajic, Marina, Blatter, Sohvi, Guyader, Charlotte, Gonggrijp, Maaike, Kersbergen, Ariena, Küçükosmanoğlu, Aslι, Sol, Wendy, Drost, Rinske, Jonkers, Jos, Borst, Piet, Rottenberg, Sven

“…We aimed to characterize and target drug-tolerant BRCA1-deficient tumor cells that cause residual disease and subsequent tumor relapse. We studied responses to…”
Get full text

Abstract 736: Combining PD1- and CTLA4-inhibiting antibodies with cisplatin or PARP inhibition in an attempt to eradicate BRCA1-deficient mouse mammary tumors by Blatter, Sohvi, Guyader, Charlotte, Küçükosmanoğlu, Aslı, Freriks, Stephan, de Visser, Karin, Borst, Piet, Rottenberg, Sven

“…Abstract Solid tumors are usually not eradicated by conventional chemotherapy resulting in disease relapse and mortality. An intriguing example is…”
Get full text

Abstract 3607: Loss-of-function screens using haploid KBM7 and HAP1 cells to identify mechanisms of anti-cancer drug resistance by Gerhards, Nora M., Guyader, Charlotte, Blomen, Vincent A., Küçükosmanoğlu, Aslı, van Tellingen, Olaf, Vis, Daniel J., Wessels, Lodewyk F., Brummelkamp, Thijn R., Borst, Piet, Rottenberg, Sven

“…Abstract The lack of biomarkers to predict anti-cancer therapy response remains a major obstacle in the treatment of various cancers. This handicap not only…”
Get full text

Subunit composition of VRAC channels determines substrate specificity and cellular resistance to P t‐based anti‐cancer drugs by Planells‐Cases, Rosa, Lutter, Darius, Guyader, Charlotte, Gerhards, Nora M, Ullrich, Florian, Elger, Deborah A, Kucukosmanoglu, Asli, Xu, Guotai, Voss, Felizia K, Reincke, S Momsen, Stauber, Tobias, Blomen, Vincent A, Vis, Daniel J, Wessels, Lodewyk F, Brummelkamp, Thijn R, Borst, Piet, Rottenberg, Sven, Jentsch, Thomas J

Get full text

Abstract 1603: Primary breast cancer xenografts maintain the molecular profiles of corresponding patients’ tumors and recapitulate a part of stroma microenvironment by Reyal, Fabien, Guyader, Charlotte, Decraene, Charles, Lucchesi, Carlo, Auger, Nathalie, Assayag, Franck, De Plater, Ludmilla, Gentien, David, Poupon, Marie-France, Cottu, Paul, De Cremoux, Patricia, Vincent-Salomon, Anne, Roman-Roman, Sergio, Delattre, Olivier, Decaudin, Didier, Marangoni, Elisabetta

“…Abstract Identifying new therapeutic agents for breast cancer (BC) treatment requires preclinical models that recapitulate the molecular characteristics of…”
Get full text

Abstract 3275: Molecular characterization of human breast cancer xenografts reveals a strong genomic and gene expression stability by Reyal, Fabien, Guyader, Charlotte, Decraene, Charles, Lucchesi, Carlo, Auger, Nathalie, Assayag, Franck, DePlater, Ludmilla, Gentien, David, Poupon, Marie-France, Cottu, Paul, Cremoux, Patricia De, Vincent-Salomon, Anne, Roman-Roman, Sergio, Delattre, Olivier, Decaudin, Didier, Marangoni, Elisabetta

“…Abstract Introduction: Identifying new therapeutic agents for breast cancer (BC) treatment requires preclinical models that recapitulate the molecular…”
Get full text

Hormone escape is associated with genomic instability in a human prostate cancer model by Legrier, Marie‐Emmanuelle, Guyader, Charlotte, Céraline, Jocelyn, Dutrillaux, Bernard, Oudard, Stéphane, Poupon, Marie‐France, Auger, Nathalie

“…Lack of hormone dependency in prostate cancers is an irreversible event that occurs through generation of genomic instability induced by androgen deprivation…”
Get full text

Abstract A27: Efficacy of estramustine + docetaxel in docetaxel-resistant human prostate cancer xenograft: a preclinical model of docetaxel resistance reversion by Dahmani, Ahmed, De Plater, Ludmilla, Guyader, Charlotte, Fontaine, Jean-Jacques, Berniard, Aurélie, Assayag, Franck, Beuzeboc, Philippe, Marangoni, Elisabetta, Némati, Fariba, Poupon, Marie-France, Pasik, Christophe, Oudard, Stéphane, Decaudin, Didier

“…Abstract Introduction: Androgen-dependent prostate cancers (PC) are usually sensitive to docetaxel chemotherapy. Nevertheless, docetaxel-resistance frequently…”
Get full text

A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancer by Dahmani, Ahmed, de Plater, Ludmilla, Guyader, Charlotte, Fontaine, Jean-Jacques, Berniard, Aurélie, Assayag, Franck, Beuzeboc, Philippe, Marangoni, Elisabetta, Némati, Fariba, Poupon, Marie-France, Pasik, Christophe, Oudard, Stéphane, Decaudin, Didier

“…Androgen-dependent and castration-resistant prostate cancer (PC) is usually sensitive to docetaxel chemotherapy. Nevertheless, docetaxel resistance frequently…”
Get full text

New targeted therapies in hormone-refractory prostate cancer by Oudard, Stéphane, Banu, Eugeniu, Scotte, Florian, Beuzeboc, Philippe, Guyader, Charlotte, Medioni, Jacques

“…Although the number of men presenting with metastatic prostate cancer has decreased significantly over the last several years, the death rate for those men is…”
Get more information

Nouveaux traitements ciblés du cancer de la prostate hormonorésistant: Les cancers de la prostate by OUDARD, Stéphane, BANU, Eugeniu, SCOTTE, Florian, BEUZEBOC, Philippe, GUYADER, Charlotte, MEDIONI, Jacques

Get full text